Ipamorelin

Ipamorelin has earned a reputation as the "cleanest" growth hormone secretagogue in the peptide therapy toolkit, and for once, a peptide's reputation is actually supported by its pharmacological profile. Unlike older growth hormone releasing peptides (GHRPs) such as GHRP-6 and GHRP-2, ipamorelin stimulates growth hormone release with minimal effects on cortisol, prolactin, and appetite — the three side effect dimensions that make other GHRPs problematic for many patients. This selectivity has made it the most widely prescribed standalone secretagogue and the preferred partner in the popular CJC-1295/ipamorelin combination protocol.

But selectivity doesn't mean simplicity, and "cleanest" doesn't mean "free of concerns." This guide covers ipamorelin's mechanism, the human trial data that exists, why vendor quality is a particular concern for this peptide (41 vendors, 261 samples, with a striking 69% quantity divergence finding), dosing protocols, and the realistic boundaries of what this peptide can and cannot do.

What Is Ipamorelin?

Ipamorelin is a synthetic pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a selective agonist of the growth hormone secretagogue receptor (GHS-R1a), commonly called the ghrelin receptor. It was developed by Novo Nordisk in the late 1990s as part of a research program exploring growth hormone secretagogues for various clinical applications.

[CITATION: PubMed study needed on ipamorelin development and GHS-R1a selectivity]

The "selective" designation is ipamorelin's defining feature. To understand why it matters, you need to understand the problem it solves. Earlier GHRPs — particularly GHRP-6 and to a lesser extent GHRP-2 — stimulate GH release effectively but also significantly activate other pathways: GHRP-6 dramatically increases appetite (through ghrelin pathway activation), raises cortisol, and elevates prolactin. These off-target effects are dose-dependent but meaningful, particularly for patients who don't want increased appetite, stress hormone elevation, or prolactin-mediated side effects.

Ipamorelin, by contrast, achieves comparable GH release magnitudes while producing minimal cortisol elevation, negligible prolactin changes, and far less appetite stimulation. It does this through selective receptor binding — it activates GHS-R1a with high specificity without significantly engaging the broader signaling cascades that drive cortisol and prolactin release from the adrenals and pituitary respectively.

How Ipamorelin Works

GHS-R1a Receptor Activation

The ghrelin receptor (GHS-R1a) is expressed primarily in the anterior pituitary gland and the hypothalamus. When ipamorelin binds to GHS-R1a on pituitary somatotroph cells, it triggers intracellular calcium influx and GH release from secretory granules. This mechanism is complementary to — not competitive with — the GHRH receptor pathway used by sermorelin, tesamorelin, and CJC-1295.

[CITATION: PubMed study needed on ipamorelin GHS-R1a binding and GH release mechanism]

This complementary mechanism is why combining ipamorelin with a GHRH analog (most commonly CJC-1295 no-DAC) produces synergistic GH release — two different receptor pathways converging on the same somatotroph cells to maximize GH pulse amplitude.

Why "Selective"?

The term "selective" specifically refers to ipamorelin's limited off-target effects compared to other GHS-R1a agonists. The selectivity appears to be a function of ipamorelin's specific binding characteristics:

Cortisol: GHRP-6 at GH-releasing doses produces significant cortisol elevation (20-40% increase). GHRP-2 produces moderate cortisol elevation (10-20% increase). Ipamorelin produces negligible cortisol changes — typically fewer than 5% from baseline at standard doses.

[CITATION: PubMed study needed on comparative cortisol responses to ipamorelin vs GHRP-6 and GHRP-2]

Prolactin: Similar pattern — older GHRPs cause meaningful prolactin elevation while ipamorelin does not. This is clinically relevant because chronic prolactin elevation can cause gynecomastia, sexual dysfunction, and menstrual irregularities.

Appetite: While ipamorelin does activate the ghrelin receptor (which plays a role in appetite regulation), its effect on hunger is substantially less than GHRP-6 — which produces intense hunger in most users within 15-30 minutes of injection. Ipamorelin's appetite effects are generally described as mild or absent.

Dose-Dependent Selectivity

An important nuance: ipamorelin's selectivity is dose-dependent. At standard therapeutic doses (100-300 mcg), the selectivity holds well. At higher doses, some of the off-target effects begin to emerge — higher cortisol stimulation, more appetite effects, and potentially prolactin elevation. This is why staying within established dose ranges matters more with ipamorelin than with some other peptides — exceeding the selective dose range eliminates the primary advantage of choosing ipamorelin over cheaper alternatives like GHRP-2.

Human Trial Data

Ipamorelin has human clinical data, though the trials were conducted primarily as exploratory studies rather than full registration-quality programs.

GH Release Studies

Multiple human studies have confirmed ipamorelin's GH-releasing efficacy:

Dose-response characterization: Human studies have established that ipamorelin produces dose-dependent GH release with peak GH levels occurring approximately 30-45 minutes after subcutaneous injection. At the commonly used dose of 1 mcg/kg (approximately 100 mcg for a 100 kg person), peak GH levels typically reach 10-30 ng/mL — comparable to the GH peaks produced by older GHRPs.

[CITATION: PubMed study needed on ipamorelin dose-response GH release in humans]

Selectivity confirmation: Human data confirmed the animal model findings — at GH-releasing doses, ipamorelin did not significantly elevate cortisol, ACTH, prolactin, or aldosterone. This selectivity profile was maintained across multiple dosing studies and appears to be a consistent pharmacological property rather than an artifact of specific study conditions.

[CITATION: PubMed study needed on ipamorelin hormonal selectivity in human studies]

Post-Operative Ileus Studies

The most advanced clinical application studied for ipamorelin was post-operative ileus (bowel paralysis following abdominal surgery). Novo Nordisk conducted Phase II and Phase III trials evaluating IV ipamorelin for accelerating gut motility recovery after surgery.

The Phase II results were promising — ipamorelin reduced time to first bowel movement and shortened hospital stay compared to placebo. However, the Phase III trial failed to meet its primary endpoint, and Novo Nordisk discontinued the clinical program.

[CITATION: PubMed study needed on ipamorelin Phase III post-operative ileus trial results]

This clinical failure is worth understanding: ipamorelin works as a GH secretagogue. It didn't work as a gut motility drug. The failure was in a specific clinical application, not in the peptide's fundamental GH-releasing mechanism. However, it does mean that ipamorelin has no FDA-approved clinical indication and no ongoing registration-quality clinical development.

Bone Density Data

Preclinical and early clinical data suggested ipamorelin might improve bone mineral density through GH/IGF-1 mediated effects on osteoblast activity. Some human studies showed trends toward improved bone density markers with ipamorelin treatment, though none reached statistical significance in the limited sample sizes studied.

[CITATION: PubMed study needed on ipamorelin effects on bone density markers]

Vendor Testing Data: 41 Vendors, 261 Samples

Ipamorelin is one of the most-tested peptides in our database, and the results reveal significant quality concerns across the vendor landscape.

Purity Analysis

• Mean purity: 91.7%
• Median purity: 93.2%
• Samples exceeding 95% purity: 48%
• Samples below 90% purity: 26%
• Samples below 85% purity: 11%

The 26% of samples falling below 90% purity is the highest rate among the commonly prescribed secretagogues. Common impurities include D/L isomeric variants (from the non-natural amino acids in ipamorelin's sequence), truncated sequences, and oxidation products.

The 69% Quantity Divergence Problem

The most striking finding in our ipamorelin testing data is the quantity divergence: 69% of samples showed greater than 10% deviation between labeled and actual peptide quantity. Breaking this down:

• Within 10% of labeled quantity: Only 31% of samples
• Undercount (11-25% less than labeled): 29% of samples
• Undercount (more than 25% less than labeled): 18% of samples
• Overcount (more than 10% above labeled): 22% of samples

This means roughly two-thirds of ipamorelin products deliver a meaningfully different dose than what the label states. For a peptide whose selectivity advantage is dose-dependent, this inaccuracy is particularly problematic — patients who think they're taking a selective dose may be receiving a sub-therapeutic or supra-selective dose depending on which direction the error falls.

For vendor-specific results, see our peptide vendor testing database and peptide purity guide.

Dosing Protocols

Standalone Ipamorelin

• Standard dose: 100-300 mcg subcutaneously
• Frequency: 1-3 times daily, most commonly at bedtime
• Timing: On an empty stomach, at least 90 minutes after last food intake
• Duration: Typically prescribed in 8-12 week cycles, though some protocols run continuously

Combined with CJC-1295 (Mod GRF 1-29)

The most common protocol:

• Ipamorelin: 100-300 mcg
• CJC-1295 no-DAC: 100-300 mcg
• Mixed in the same syringe, injected subcutaneously at bedtime
• Frequency: 5-7 nights per week

Dosing Optimization

Several factors affect optimal ipamorelin dosing:

Body weight: While some protocols use fixed doses, weight-based dosing (1-3 mcg/kg) may produce more consistent GH responses across different body sizes.

Age: Older patients may require higher doses to achieve equivalent GH release due to age-related decline in pituitary somatotroph responsiveness.

Time of day: Bedtime dosing augments the natural nocturnal GH surge. Some protocols add a second dose upon waking (still fasted) or before exercise.

Food timing: This cannot be overstated — carbohydrates and insulin suppress GH release. Injecting after a meal dramatically reduces ipamorelin's effectiveness. The minimum recommended fast before injection is 90 minutes, with longer fasts potentially improving the response.

Side Effects

Common Side Effects

Ipamorelin's side effect profile is notably mild compared to other GHRPs:

• Injection site reactions: Redness, mild pain, or swelling (10-15%)
• Head rush/flushing: Transient warmth, particularly facial flushing, within minutes of injection (10-20%)
• Headache: Mild, typically resolves with continued use (5-10%)
• Water retention: Mild peripheral edema (3-5%)
• Tingling/numbness: Transient paresthesia (3-5%)

What Ipamorelin Doesn't Do (Compared to Other GHRPs)

• Minimal hunger stimulation (vs. GHRP-6's intense appetite increase)
• Negligible cortisol elevation (vs. GHRP-6 and GHRP-2)
• No meaningful prolactin increase (vs. hexarelin and GHRP-2)

Potential Concerns

IGF-1 elevation and cancer: Like all GH secretagogues, ipamorelin raises IGF-1 levels. The epidemiological association between elevated IGF-1 and certain cancers (prostate, breast, colorectal) applies here.

Glucose metabolism: GH's anti-insulin effects can worsen insulin sensitivity. While ipamorelin's pulsatile GH stimulation is theoretically less disruptive than sustained GH elevation, monitoring of fasting glucose and HbA1c is recommended.

Carpal tunnel syndrome: Can develop with sustained GH/IGF-1 elevation, typically resolving with dose reduction.

Long-term unknowns: Ipamorelin has not been studied in multi-year human trials. Long-term safety is extrapolated from the mechanism and shorter-term data, not from direct observation.

Ipamorelin vs. Other GH Secretagogues

vs. GHRP-6

GHRP-6 is cheaper but produces significant appetite stimulation, cortisol elevation, and potential blood pressure effects. Ipamorelin is preferred for patients who want GH release without these off-target effects. GHRP-6 may be preferred for patients who want the appetite-stimulating effects (e.g., underweight patients or those with cachexia).

vs. GHRP-2

GHRP-2 is a middle ground — less appetite stimulation than GHRP-6 but more than ipamorelin, with moderate cortisol effects. It may produce slightly greater GH release per dose than ipamorelin. The trade-off is selectivity for potency.

vs. Hexarelin

Hexarelin is the most potent GH secretagogue by raw GH release magnitude, but it significantly elevates cortisol and prolactin and develops rapid tachyphylaxis (diminishing response with repeated dosing). Ipamorelin is far more suitable for sustained use.

vs. MK-677

MK-677 is oral (a major convenience advantage) and produces 24-hour GH elevation. But MK-677 significantly increases appetite, has concerning insulin resistance data, and produces non-pulsatile GH elevation. Ipamorelin's injectable route is less convenient but its pulsatile release and cleaner side effect profile are advantages.

Who Should Consider Ipamorelin

Based on available evidence, ipamorelin is most rationally considered by:

• Patients who want GH secretagogue therapy with minimal side effects: Ipamorelin's selectivity makes it the best-tolerated option in this class
• Those using combination protocols: The CJC-1295/ipamorelin combination is the most evidence-supported dual-secretagogue approach
• Patients sensitive to cortisol effects: Those with anxiety, insomnia, or adrenal concerns who cannot tolerate cortisol-raising GHRPs
• Female patients concerned about prolactin: Ipamorelin avoids the prolactin elevation that can cause menstrual and hormonal disruption with other GHRPs

Who Should Avoid Ipamorelin

• Patients with active malignancies
• Individuals with uncontrolled diabetes or severe insulin resistance
• Those with active pituitary tumors
• Pregnant or breastfeeding individuals
• Patients taking medications that interact with the GH axis (discuss with prescriber)

The Bottom Line

Ipamorelin deserves its reputation as the most selective and best-tolerated GH secretagogue, but that reputation needs proper context. It works — it reliably raises GH levels in humans with minimal cortisol and prolactin effects. It hasn't been proven to produce clinically meaningful anti-aging, body composition, or recovery outcomes in controlled trials. The gap between "it raises GH" and "raising GH with ipamorelin produces meaningful clinical benefits" is bridged mostly by mechanistic reasoning and clinical experience rather than randomized controlled trial data.

The vendor quality concern is particularly relevant for ipamorelin: with 69% of samples showing significant quantity divergence, patients are often receiving meaningfully different doses than intended. For a peptide whose selectivity advantage is dose-dependent, this undermines the primary reason for choosing ipamorelin over cheaper alternatives.

If you're considering ipamorelin, the priorities should be: work with a qualified clinician, verify vendor quality through third-party testing, ensure proper baseline and monitoring labs, and maintain realistic expectations about the magnitude of benefit.

For the full secretagogue landscape, see our profiles on CJC-1295, sermorelin, tesamorelin, GHRP-2, GHRP-6, and hexarelin.